Qingke Pingchuan granules for adult community-acquired pneumonia with syndrome of phlegm heat obstructing lung: a randomized, double-blind, placebo-controlled trial
- Conditions
- Community-Acquired Pneumonia
- Registration Number
- ITMCTR2100004416
- Lead Sponsor
- Guangdong Provincial Hospital of Chinese Medicine
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- Not specified
1. Patients who are aged 18–65 years;
2. Patients who meet the diagnostic criteria of CAP;
3. Patients who meet the Chinese medicine syndrome classification of phlegm heat obstructing lung;
4. CURB-65 score is 0-2 points;
5. Patients who sign the written informed consent form.
1. Severe pneumonia;
2. Other respiratory diseases: bronchial asthma, bronchiectasis, bullae, pleural effusion, active tuberculosis and other lung diseases;
3. Severe or uncontrollable basic diseases:hematological diseases; liver dysfunction (ALT or AST >= 3ULN, total bilirubin >= 1.5ULN), renal dysfunction (serum creatinine > 177µmol/L or 2mg/dl), congestive heart failure (III-IV); immune deficiency, tumor, organ or bone marrow transplantation, HIV or immunosuppressive therapy in recent 3 months;
4. Patients with diabetes or impaired glucose tolerance;
5. Patients with confirmed history of alcohol, drug abuse or mental illness;
6. Patients with dysphagia or gastrointestinal disease affecting drug absorption (reflux esophagitis, chronic diarrhea, inflammatory bowel disease, intestinal tuberculosis, gastrinoma, short bowel syndrome, after subtotal gastrectomy);
7. Patients who have known hypersensitivity to the study medication or some of its ingredients;
8. Patines have been exposed to the study drug within one month before enrollment;
9. Patients who are pregnant or lactating.
Study & Design
- Study Type
- Interventional study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Modified imaging absorption assessment scale for pneumonia;
- Secondary Outcome Measures
Name Time Method WBC;Classification of sputum cytology;CASA-Q;The proportion and time of phlegm disappearance;CRP;CURB-65;PCT;Cough symptom score;Average treatment days;The proportion and time of cough disappearance;